Comparison 16. BUD v BUD: Crossover design, oral steroid treated: 400 v 1600 mcg/d.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 FEV1 (litres)	1	48	Mean Difference (IV, Fixed, 95% CI)	‐0.25 [‐0.72, 0.22]
1.1 Children	0	0	Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.2 Adults	1	48	Mean Difference (IV, Fixed, 95% CI)	‐0.25 [‐0.72, 0.22]
2 FVC (litres)	1	48	Mean Difference (IV, Fixed, 95% CI)	‐0.33 [‐0.96, 0.30]
2.1 Children	0	0	Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.2 Adults	1	48	Mean Difference (IV, Fixed, 95% CI)	‐0.33 [‐0.96, 0.30]
3 Morning PEFR (L/min)	2	84	Mean Difference (IV, Fixed, 95% CI)	‐20.62 [‐63.01, 21.78]
3.1 Children	0	0	Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
3.2 Adults	2	84	Mean Difference (IV, Fixed, 95% CI)	‐20.62 [‐63.01, 21.78]
4 Evening PEFR (L/min)	2	84	Mean Difference (IV, Fixed, 95% CI)	‐15.29 [‐52.33, 21.75]
4.1 Children	0	0	Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.2 Adults	2	84	Mean Difference (IV, Fixed, 95% CI)	‐15.29 [‐52.33, 21.75]
5 Daily beta2 agonist use (puffs/day)	2	84	Mean Difference (IV, Fixed, 95% CI)	‐0.09 [‐1.51, 1.34]
5.1 Children	0	0	Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
5.2 Adults	2	84	Mean Difference (IV, Fixed, 95% CI)	‐0.09 [‐1.51, 1.34]
6 Daytime breathlessness score	2	84	Std. Mean Difference (IV, Fixed, 95% CI)	0.00 [‐0.43, 0.43]
6.1 Children	0	0	Std. Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
6.2 Adults	2	84	Std. Mean Difference (IV, Fixed, 95% CI)	0.00 [‐0.43, 0.43]
7 Night‐time breathlessness score	2	84	Std. Mean Difference (IV, Fixed, 95% CI)	0.12 [‐0.31, 0.55]
7.1 Children	0	0	Std. Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
7.2 Adults	2	84	Std. Mean Difference (IV, Fixed, 95% CI)	0.12 [‐0.31, 0.55]